New Document top_band
 
Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Read more on:    Doxil | Cancer | Sun Pharma
Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug .

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Quick Links

 

Market News

Today's picks

Nifty, Bank Nifty, Wipro, Cairn & Hind Unilever

CSE to fund stake buyout in clearing corp by selling land

CSE needs to either tie-up with a clearing corporation or pick up a stake in it clearing corporation to meet the norms for regional stock ...

Sebi bars Sunplant, its directors from mobilising funds

Market regulator said the company raised a little over Rs 24 crore from over 3,200 investors through redeemable preference shares

Foreign investors allowed to take fresh positions in IRF

Exchanges allowed foreign investors to take further long positions in IRF

Sebi tweaks investment cap for FPIs in G-Secs

Sub-limit for longer time FPIs has been reduced by $5 billion as there was less demand in this category

Back to Top